GlassScriptPhysician profile
Rona A Eikey
NPI 1639482326
$2,421.79
in general payments reported to CMS, 2019-2025
14 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $686 · 2022: $1,112 · 2023: $484 · 2024: $20.62 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $603 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $602.54 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $424.19 | 2021-2023 | Brilinta, Farxiga |
| Janssen Pharmaceuticals, INC | $355.10 | 2021-2023 | Xarelto |
| Pfizer INC. | $327.53 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $210.25 | 2022-2023 | Eliquis |
| Amgen INC. | $202.37 | 2021-2023 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $200.10 | 2023-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $189.61 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $154.31 | 2021-2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.39 | 2021-2023 | Jardiance |
| Heartflow, INC. | $86.02 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $77.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $16.19 | 2021 | |
| Amarin Pharma, INC. | $15.52 | 2021 | |
| Zoll Circulation INC | $11.21 | 2023 | Catheter, Downstream Cartridge, Therox Ds2 Console |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rona Eikey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.